{"id":"uroxatrol-drug","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Retrograde ejaculation"}]},"_chembl":{"chemblId":"CHEMBL157030","moleculeType":"Small molecule","molecularWeight":"883.99"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug selectively blocks alpha-1A adrenergic receptors, which are predominantly expressed in the prostate and bladder outlet. By antagonizing these receptors, Uroxatrol reduces smooth muscle tone in the prostate and bladder neck, thereby decreasing urethral resistance and improving urinary flow rate in patients with benign prostatic hyperplasia (BPH).","oneSentence":"Uroxatrol is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:10.271Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms"}]},"trialDetails":[{"nctId":"NCT06316336","phase":"PHASE1","title":"Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions","status":"NOT_YET_RECRUITING","sponsor":"Pharma Nueva","startDate":"2024-06-10","conditions":"Healthy Vollunteer","enrollment":44},{"nctId":"NCT06228339","phase":"PHASE1","title":"The Bioequivalence Study of Alfuzosin 10 mg Prolong-released Tablets Under Fed Conditions","status":"UNKNOWN","sponsor":"International Bio service","startDate":"2024-03-09","conditions":"Healthy Volunteer","enrollment":44},{"nctId":"NCT00836823","phase":"PHASE4","title":"Evaluation of Symptom-specific Goal Achievement","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2005-12","conditions":"Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms","enrollment":130},{"nctId":"NCT00256399","phase":"NA","title":"Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2005-11","conditions":"BPH, Erectile Dysfunction","enrollment":6},{"nctId":"NCT05094947","phase":"NA","title":"Intermittent Catheterization Versus Trial Without Catheter","status":"UNKNOWN","sponsor":"Moscow State University of Medicine and Dentistry","startDate":"2021-08-03","conditions":"Benign Prostatic Hyperplasia","enrollment":200},{"nctId":"NCT00696761","phase":"PHASE4","title":"The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2006-05","conditions":"BPH","enrollment":232},{"nctId":"NCT00103402","phase":"PHASE3","title":"Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2005-02","conditions":"Prostatitis","enrollment":272},{"nctId":"NCT01834729","phase":"PHASE2","title":"Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-03","conditions":"Constipation","enrollment":74},{"nctId":"NCT00893113","phase":"PHASE3","title":"An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Chesapeake Urology Research Associates","startDate":"2009-06","conditions":"Erectile Dysfunction, Lower Urinary Tract Symptoms","enrollment":74},{"nctId":"NCT01323998","phase":"","title":"Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Prostatic Hyperplasia","enrollment":35032},{"nctId":"NCT01332435","phase":"","title":"Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Prostatic Hyperplasia","enrollment":6896},{"nctId":"NCT01332487","phase":"","title":"Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Prostatic Hyperplasia","enrollment":4068},{"nctId":"NCT01386983","phase":"","title":"Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Prostatic Hyperplasia","enrollment":332},{"nctId":"NCT01390870","phase":"","title":"Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Prostatic Hyperplasia","enrollment":400},{"nctId":"NCT01435954","phase":"","title":"Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Benign Prostatic Hyperplasia","enrollment":13551},{"nctId":"NCT03144596","phase":"PHASE4","title":"The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil","status":"COMPLETED","sponsor":"Kocatepe University","startDate":"2015-10-29","conditions":"Benign Prostatic Hyperplasia, Pupil Anomaly, Choroid Disease","enrollment":63},{"nctId":"NCT02977832","phase":"NA","title":"Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2015-01","conditions":"Benign Prostatic Hypertrophy With Outflow Obstruction, Benign Prostatic Hyperplasia","enrollment":30},{"nctId":"NCT00388271","phase":"PHASE3","title":"Use of Alfuzosin in Stone Treatment With ESWL","status":"WITHDRAWN","sponsor":"Singapore General Hospital","startDate":"2006-10","conditions":"Urinary Calculi","enrollment":""},{"nctId":"NCT00583258","phase":"NA","title":"A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones","status":"WITHDRAWN","sponsor":"Unity Health Toronto","startDate":"2007-10","conditions":"Kidney Stones","enrollment":""},{"nctId":"NCT00576823","phase":"PHASE3","title":"Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-12","conditions":"Hydronephrosis, Neurogenic Bladder","enrollment":25},{"nctId":"NCT00549939","phase":"PHASE3","title":"Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Neurogenic Urinary Bladder","enrollment":172},{"nctId":"NCT02266537","phase":"PHASE1","title":"Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11","conditions":"Healthy","enrollment":97},{"nctId":"NCT00679315","phase":"PHASE2","title":"Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2008-06","conditions":"Voiding Dysfunction","enrollment":190},{"nctId":"NCT00687388","phase":"PHASE4","title":"The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia","status":"WITHDRAWN","sponsor":"Samsung Medical Center","startDate":"2008-05","conditions":"Benign Prostatic Hyperplasia","enrollment":""},{"nctId":"NCT00467467","phase":"PHASE3","title":"Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-06","conditions":"Ureteral Stent Discomfort","enrollment":60},{"nctId":"NCT00451061","phase":"PHASE4","title":"The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2007-04","conditions":"Renal Colic","enrollment":120},{"nctId":"NCT00713739","phase":"PHASE3","title":"Alfuzosin for Medical Expulsion Therapy of Ureteral Stones","status":"UNKNOWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2008-01","conditions":"Kidney Stones","enrollment":240},{"nctId":"NCT01418599","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01418586","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fasted Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00688948","phase":"PHASE2, PHASE3","title":"Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)","status":"TERMINATED","sponsor":"Nova Scotia Health Authority","startDate":"2007-11","conditions":"Multiple Sclerosis, Bladder Dysfunction","enrollment":20},{"nctId":"NCT00563654","phase":"NA","title":"Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up","status":"TERMINATED","sponsor":"Hospital Authority, Hong Kong","startDate":"2005-10","conditions":"Prostatic Hyperplasia, Urinary Retention, Acute Disease","enrollment":48},{"nctId":"NCT00280605","phase":"PHASE4","title":"ALF-ONE : ALFuzosin ONcE Daily","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-08","conditions":"Prostatic Hyperplasia","enrollment":200},{"nctId":"NCT00941343","phase":"NA","title":"Benign Prostatic Hyperplasia in Taiwan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Prostatic Diseases","enrollment":362},{"nctId":"NCT00064649","phase":"PHASE3","title":"Minimally Invasive Surgical Therapy for BPH","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-04","conditions":"Benign Prostatic Hyperplasia","enrollment":49},{"nctId":"NCT00629720","phase":"PHASE3","title":"Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-07","conditions":"Urinary Bladder Neurogenic","enrollment":29},{"nctId":"NCT00399464","phase":"PHASE3","title":"Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-11","conditions":"Prostatic Hyperplasia","enrollment":1177},{"nctId":"NCT00409357","phase":"PHASE2","title":"Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-11","conditions":"Benign Prostatic Hyperplasia","enrollment":473},{"nctId":"NCT00347061","phase":"PHASE3","title":"Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Benign Prostatic Hyperplasia","enrollment":148},{"nctId":"NCT00486785","phase":"PHASE4","title":"SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-04","conditions":"Prostatic Hyperplasia","enrollment":431},{"nctId":"NCT00401661","phase":"PHASE4","title":"Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Prostatic Hyperplasia","enrollment":110},{"nctId":"NCT00336921","phase":"PHASE2","title":"Alfuzosin for Treating Acute Urinary Retention","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Acute Urinary Retention","enrollment":156},{"nctId":"NCT00290030","phase":"PHASE3","title":"ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-05","conditions":"Prostatic Hyperplasia, Acute Urinary Retention","enrollment":800},{"nctId":"NCT00409227","phase":"PHASE2","title":"Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2006-12","conditions":"Urolithiasis, Nephrolithiasis, Ureterolithiasis","enrollment":150},{"nctId":"NCT00029822","phase":"PHASE3","title":"Clinical Trial in Males With BPH (Enlarged Prostate)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-05","conditions":"Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy","enrollment":1522},{"nctId":"NCT00575913","phase":"PHASE4","title":"Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-09","conditions":"Prostatic Diseases","enrollment":118},{"nctId":"NCT00637715","phase":"PHASE4","title":"Once Daily Given Alfuzosin in the Treatment of BPH","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-10","conditions":"Benign Prostatic Hyperplasia","enrollment":60},{"nctId":"NCT00427882","phase":"PHASE4","title":"Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2006-09","conditions":"Prostatic Hyperplasia","enrollment":125},{"nctId":"NCT00542165","phase":"PHASE4","title":"Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-03","conditions":"BPH/LUTS/Sexual Functions","enrollment":166},{"nctId":"NCT00540891","phase":"PHASE3","title":"The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-02","conditions":"Benign Prostatic Hyperplasia","enrollment":372},{"nctId":"NCT00454402","phase":"PHASE3","title":"ALF-STONE: Alfuzosin in Uretheric Stones","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-08","conditions":"Prostatic Hyperplasia","enrollment":220},{"nctId":"NCT00453908","phase":"PHASE3","title":"Alfuzosin Versus Placebo in Acute Urinary Retention","status":"TERMINATED","sponsor":"Sanofi","startDate":"2004-05","conditions":"Urinary Retention","enrollment":160},{"nctId":"NCT00397397","phase":"","title":"Comparative Treatment Study in Patients With Lower Ureteral Stones","status":"UNKNOWN","sponsor":"Hillel Yaffe Medical Center","startDate":"2007-01","conditions":"Urinary Calculi","enrollment":60},{"nctId":"NCT00201630","phase":"PHASE3","title":"Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy","status":"UNKNOWN","sponsor":"New York Prostate Institute","startDate":"2005-09","conditions":"Prostate Cancer","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Uroxatrol (drug)","genericName":"Uroxatrol (drug)","companyName":"New York Prostate Institute","companyId":"new-york-prostate-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Uroxatrol is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. Used for Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}